Merck’s anti-COVID pill remains “active” against Omicron variants, a US pharmaceutical company said Friday, citing the results of six laboratory studies.
Oral treatment, called molnupiravir, is given within 5 days of the onset of symptoms and can reduce COVID hospitalization and death in risky people by 30% in a pre-Omicron study of 1,400 participants. Shown.
The latest in vitro studies based on cell-based assays were independently conducted by researchers from six countries: Belgium, Germany, the Czech Republic, Poland, the Netherlands and the United States.
The results show that “molnupiravir has consistent antiviral activity against Omicron, the major variant in the world,” said Dean Y. Li of the Merck Institute. President Lee said in a statement.
These findings “provide additional confidence in the potential of molnupiravir as an important treatment option for certain adults with mild to moderate COVID-19 who are at high risk of developing severe disease,” he said. rice field.
The effectiveness of molnupiravir on Omicron has not yet been evaluated Clinical trials, Merck, known as MSD outside the United States and Canada, said.
The treatment, sometimes sold under the name Lagevrio, has been approved in more than 10 countries, including the United States, United Kingdom, and Japan.
According to the company, Washington has paid $ 2.2 billion for 3.1 million courses of treatment in Merck, of which 2 million have already been offered.
A total of 10 million courses will be created in 2021, and Merck plans to create another 20 million courses this year.
Take 8 capsules of molnupiravir orally for 5 days for a total of 40 capsules.
Pfizer has also developed an anti-COVID pill sold as Paxlovid. Pfizer tablets reduce the same results as Merck by almost 90% and are approved for people over the age of 12, reducing overall safety concerns.
A US pharmaceutical company said in mid-January that in vitro studies suggest that Paxlovid should remain effective against Omicron.
Other treatments for COVID-19, such as Regeneron and Eli Lilly’s monoclonal antibodies, have been shown to be ineffective against Omicron. The US Food and Drug Administration restricted their use earlier this week.
Omicron strains, especially scattered on the surface of the virus, have numerous mutations in the key spike proteins for entry into human cells. As a result, some treatments are ineffective against mutants.
However, because antiviral drugs do not target proteins, Mutant Confidence in proof and encouragement for the sustained efficacy of the drug, including for future variants.
© 2022 AFP
Quote: Merck states that Covid Pill is “active” to Omicron (January 28, 2022).
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Merck says Covid pill ‘active’ against Omicron Source link Merck says Covid pill ‘active’ against Omicron
The post Merck says Covid pill ‘active’ against Omicron appeared first on California News Times.